MedTrace Logo

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

NCT01034410 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2011-02-02

No results posted yet for this study

Summary

This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.

Conditions

Interventions

DRUG

AS1411

AS1411 40mg/kg/day or AS1411 80mg/kg/day

DRUG

Cytarabine

Cytarabine 2g/m2 bid Days 4-7

Sponsors & Collaborators

  • Antisoma Research

    lead INDUSTRY

Principal Investigators

  • Rob Stuart, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Australia
  • New Zealand
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01034410 on ClinicalTrials.gov